Canaccord Genuity Maintains a 'Buy' on OraSure Technologies (OSUR); Focus on 2012 Catalysts
Tweet
Share
E-mailGet Alerts OSUR Hot Sheet
Price: $3.88 +3.74%
Rating Summary:
9 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
9 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on OraSure Technologies (NASDAQ: OSUR) price target of $14.00.
Analyst, Jeffrey Frelick, said, "We reiterate our rating on OSUR following in-line Q1 results, early traction with new rapid HCV test, and an upcoming FDA panel...012 potential catalysts. 1) Change in the recommended HCV testing guidelines H1/12; 2) Quarterly HCV sales demonstrating uptake; 3) Positive FDA advisory panel in May for HIV-OTC; 4) Early FDA approval for HIV-OTC in H2/12."
For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.
Shares of OraSure Technologies closed at $11.07 yesterday.
Analyst, Jeffrey Frelick, said, "We reiterate our rating on OSUR following in-line Q1 results, early traction with new rapid HCV test, and an upcoming FDA panel...012 potential catalysts. 1) Change in the recommended HCV testing guidelines H1/12; 2) Quarterly HCV sales demonstrating uptake; 3) Positive FDA advisory panel in May for HIV-OTC; 4) Early FDA approval for HIV-OTC in H2/12."
For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.
Shares of OraSure Technologies closed at $11.07 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Deere (DE) PT Raised to $585 at JPMorgan
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
